Abstract
Chimeric antigen receptor T (CAR-T) cells directed against CD19 have transformed the therapy of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). A recent study reports promising activity and safety of CD19 CAR-T cells generated from naïve, stem, and central memory T cells in adults with R/R B-ALL. See related article by Aldoss et al., p. 742.
©2022 American Association for Cancer Research.
Publication types
-
Editorial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antigens, CD19 / immunology
-
Cell- and Tissue-Based Therapy
-
Humans
-
Immunotherapy, Adoptive
-
Memory T Cells
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / immunology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
-
Receptors, Chimeric Antigen* / genetics
-
Receptors, Chimeric Antigen* / immunology
Substances
-
Receptors, Chimeric Antigen
-
Antigens, CD19